Australia has secured a deal to receive 15,000 doses of a COVID-19 drug named Ronapreve which will assist hospitals in treating patients with severe illness.
The antibody-based therapy from Roche Products is expected to be available by the end of the month, pending regulatory approval.
Ronapreve is used to help treat COVID-19 positive patients who have no effective immune system, and will help those who contract the virus despite being unvaccinated.
Health Minister Greg Hunt said nationally, Australia has hit a first-dose vaccination rate of 84.6 per cent.
Nationally the fully vaccinated rate now sits at 67.8 per cent.
Chief Medical Officer Professor Paul Kelly said from midnight Tuesday October 19, quarantine-free international travel from the South Island of New Zealand will resume.
No date has been set for the country's North Island.